Informace o publikaci

Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno

Autoři

SKŘIČKOVÁ Jana CHLOUPKOVÁ Renata TOMÍŠKOVÁ Marcela JAKUBÍKOVÁ Lenka ŠPELDOVÁ Jana KADLEC Bohdan VENCLÍČEK Ondřej BRATOVÁ Monika BENEJOVÁ Andrea MERTA Zdeněk

Rok publikování 2019
Druh Článek v odborném periodiku
Časopis / Zdroj Studia pneumologica et phthiseologica
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www Scopus
Klíčová slova Advanced non-small cell lung cancer; Bevacizumab; Carboplatin; Oral vinorelbine; Treatment
Popis For patients with advanced NSCLC of non-squamous morphological diagnosis in whom neither epidermal growth factor receptor-activating mutation nor anaplastic lymphoma kinase gene rearrangement have been found, one possible treatment option is platinum-based chemotherapy in combination with bevacizumab. If after 4 to 6 cycles of this treatment, regression or disease stabilization is achieved, bevacizumab is further given as monotherapy (maintenance follow-up treatment). If bevacizumab treatment is indicated, the most common combination used in our center is bevacizumab with carboplatin and oral vinorelbine. The primary aim of the study was to evaluate the efficacy and safety of this approach. Treatment of 70 patients with advanced non-squamous NSCLC with the above combination was effective. So far, the median time to progression has been 5.1 months and the median survival 20.5 months. The therapy is very well tolerated.